2,3,4,5-Tetrahydro-benzothiepin-1,1-dioxid | 5395-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 2,3,4,5-Tetrahydro-benzothiepin-1,1-dioxid
• 英文别名: 2,3,4,5-Tetrahydro-1-benzothiepine 1,1-dioxide；2,3,4,5-tetrahydro-1λ6-benzothiepine 1,1-dioxide
• CAS: 5395-30-2
• 化学式: C₁₀H₁₂O₂S
• 分子量: 196.27
• InChiKey: TZSDMELQUACXIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,4,5-Tetrahydro-benzothiepin-1,1-dioxid 、 二甲胺 在 二甲胺 、 乙酸乙酯 、 水 、 magnesium sulfate 、 silica gel 作用下， 反应 16.0h， 以gave 12.43 g (90.5%) of the enantiomerically-enriched 7-(dimethylamino)tetrahydrobenzothiepine-1,1-dioxide ((4R,5R)-XXVI) as a colorless solid的产率得到7-(dimethylamino)tetrahydrobenzothiepine-1,1-dioxide
  参考文献：
  名称：

  Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides

  摘要：

  制备对映富集的四氢苯并噻吩氧化物的过程包括环化对映富集的芳基-3-丙醛亚磺酸盐，其中芳基-3-丙醛亚磺酸盐的硫原子是手性中心。

  公开号：

  US06875877B2
• 作为产物：
  描述：

  3,4-二氢-2H-苯并[B]硫杂卓-5-酮 在 盐酸 、 amalgamated zinc 、 双氧水 、 溶剂黄146 作用下， 生成 2,3,4,5-Tetrahydro-benzothiepin-1,1-dioxid
  参考文献：
  名称：

  Friedel—Crafts Cyclization of ι-Phenylalkanesulfonyl Chlorides¹

  摘要：

  DOI：

  10.1021/ja01124a031

文献信息

• Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
  申请人：Graziano P. Michael

  公开号：US20050096307A1

  公开（公告）日：2005-05-05

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one lipid modulating agent; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种脂质调节剂；和(b)至少一种取代的噁唑烷酮或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖以及降低血浆中甾醇或5α-甾烷醇的水平。
• Combinations of substituted azetidinones and CB1 antagonists
  申请人：Veltri P. Enrico

  公开号：US20060069080A1

  公开（公告）日：2006-03-30

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB 1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种选择性CB1拮抗剂；和(b)至少一种取代的氮杂环丁烷或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖、代谢综合征以及降低血浆中的甾醇或5α-甾烷醇水平。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20150119345A1

  公开（公告）日：2015-04-30

  Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.

  本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂治疗或预防胃肠和/或肝感染的方法。本文还提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂增加患有胃肠感染或肝感染的个体体内肠内分泌肽或激素水平的方法。
• Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20130108573A1

  公开（公告）日：2013-05-02

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了一种治疗或改善高胆固醇血症或胆汁淤积性肝病的方法，即通过向需要的个体施用治疗有效量的顶端钠依赖性胆酸转运蛋白抑制剂（ASBTI）或其药用可接受盐。还提供了一种治疗或改善肝病、降低血清胆酸或肝内胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法，即通过向需要的个体施用治疗有效量的ASBTI或其药用可接受盐。
• TREATING PAIN, DIABETES, AND DISORDERS OF LIPID METABOLISM
  申请人：Harris M. Joel

  公开号：US20080070892A1

  公开（公告）日：2008-03-20

  Disclosed is a method of treating a disease or condition (e.g., pain, diabetes or disorders of lipid metabolism) comprising administering an azetidine derivative of the formula I selected from the group consisting of the compounds defined by Tables 1, 2, 3a, 3b, 3c, 3d and 4a.

  揭示了一种治疗疾病或病症（例如疼痛、糖尿病或脂质代谢紊乱）的方法，包括给予从表1、2、3a、3b、3c、3d和4a定义的化合物组中选择的式I的吖啶衍生物。